Search Results 221-230 of 16635 for alopecia

1. Apalutamide (oral route) - Mayo Clinic

   Description. Apalutamide is used to treat patients with metastatic castration-sensitive prostate cancer (prostate cancer that responds to medical or ...

2. Publications - Tufia C. Haddad, M.D. - Mayo Clinic

   ... alopecia in breast cancer. Support Care Cancer. 2024 Jun 6; 32 (7):412 Epub 2024 June 06. View PubMed; Haemmerle R, Paludo J, Haddad TC, Pritchett JC. The ...

3. Nonmelanoma skin cancer - Doctors and departments - Mayo Clinic

   ... Alopecia areata, Melasma, Vascular anomaly, Dermatitis, Morphea, Skin problems, Vulvar skin disorder, Breast skin change, Rosacea, Pigmentation disorder ...

4. A Study to Evaluate Binimetinib in Combination with Encorafenib in Patients with Pancreatic Malignancies and a Somatic BRAFV600E Mutation - Mayo Clinic

   EXCEPTIONS: Stable chronic conditions (≤ grade 2) that are not expected to resolve (such as neuropathy, myalgia, alopecia, prior therapy-related ...

5. Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer - Mayo Clinic

   ... alopecia and peripheral sensory neuropathy. - Subjects of childbearing potential agree to use two forms of medically approved contraception while taking the ...

6. Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma (HIMALAYA) - Mayo Clinic

   ... alopecia, vitiligo, and the laboratory values defined in the inclusion criteria: Patients with Grade ≥2 neuropathy will be evaluated on a case-by-case ...

7. A Study Using Targeted Inhibitors to Treat Specific Tumor Mutations in Patients with Meningiomas - Mayo Clinic

   ... alopecia and fatigue; No craniotomy within 28 days of registration. Not pregnant and not nursing. A female of childbearing potential is a sexually mature ...

8. Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors - Mayo Clinic

   ... alopecia) and/or in whom ≥ 25% of the bone marrow was irradiated. Major surgery ≤ 14 days prior to registration or has not recovered from major side ...

9. Dose-Escalation Study of cevostamab (BFCR4350A) in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) - Mayo Clinic

   Any grade alopecia;; Peripheral sensory or motor neuropathy must have resolved to Grade ≤ 2. Measurable disease defined as at least one of the following ...

10. Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy - Mayo Clinic

    Any ongoing toxicity from prior anti-cancer therapy that is > grade 1 and/or that is progressing in severity (except alopecia). Uncontrolled intercurrent ...